Inod Stock Analysis: Growth Potential in Generic Injectables Sector
Published on May 28, 2024 Inod Pharmaceuticals, a mid-cap biotech firm specializing in generic injectable drugs, has quietly become a focal point for investors seeking undervalued opportunities in the healthcare sector. With a market capitalization hovering around $1.8 billion as of early 2024, the company operates at the intersection of cost efficiency and essential pharmaceutical…